What's in Teva Pharmaceutical's pipeline?

Teva Pharmaceutical has 18 drugs in our index: 17 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Teva Pharmaceutical's portfolio?

Top competitors by shared drug class: , Pfizer, Merck & Co., Bausch Health, Novartis.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/teva.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-13 · How we verify

Teva Pharmaceutical — Portfolio Competitive Intelligence Brief

Teva Pharmaceutical (TEVA) pipeline: 17 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

TEVA (NYSE) 17 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Ajovy	FREMANEZUMAB	marketed		Calcitonin gene-related peptide 1	Neuroscience	2018-01-01
Austedo	DEUTETRABENAZINE	marketed		Synaptic vesicular amine transporter	Metabolic	2017-01-01
Cinqair	RESLIZUMAB	marketed	Interleukin-5 Antagonist [EPC]	Interleukin-5	Respiratory	2016-01-01
Synribo	OMACETAXINE MEPESUCCINATE	marketed	omacetaxine mepesuccinate		Oncology	2012-01-01
Istodax	ROMIDEPSIN	marketed	Histone Deacetylase Inhibitor	HDACs	Oncology	2009-01-01
Azilect	RASAGILINE	marketed	Monoamine Oxidase Inhibitor	5-hydroxytryptamine receptor 6	Metabolic	2006-01-01
Mycamine	MICAFUNGIN	marketed	Echinocandin Antifungal	ATP-binding cassette sub-family G member 2	Infectious Disease	2005-01-01
Copaxone	GLATIRAMER ACETATE	marketed			Immunology	1996-01-01
Zebeta	BISOPROLOL	marketed	beta-Adrenergic Blocker	Beta-1 adrenergic receptor	Cardiovascular	1992-01-01
Cutivate	FLUTICASONE PROPIONATE	marketed	Corticosteroid	Glucocorticoid receptor	Oncology	1990-01-01
Orap	PIMOZIDE	marketed	Typical Antipsychotic [EPC]	5-hydroxytryptamine receptor 7	Neuroscience	1984-01-01
Zanosar	STREPTOZOCIN	marketed	Alkylating Drug [EPC]		Oncology	1982-01-01

Therapeutic area mix

Neuroscience · 4
Oncology · 4
Immunology · 3
Metabolic · 2
Cardiovascular · 1
Respiratory · 1
Dermatology · 1
Infectious Disease · 1
Other · 1

Recent regulatory actions (last 90 days)

2026-03-03 — Cutivate · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

· 6 shared drug classes
Pfizer · 5 shared drug classes
Merck & Co. · 4 shared drug classes
Bausch Health · 3 shared drug classes
Novartis · 2 shared drug classes
AbbVie · 2 shared drug classes
AstraZeneca · 2 shared drug classes
Specgx Llc · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Teva Pharmaceutical:

Cite this brief

Drug Landscape (2026). Teva Pharmaceutical — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/teva. Accessed 2026-05-13.